Loading ...
Sorry, an error occurred while loading the content.
 

Amantadine/Interferon-Alpha/Ribavarin Retreatment in Non-Responder Patients with Chronic Hepatitis C

Expand Messages
  • claudine intexas
    Some Improvements Observed with Amantadine/Interferon-Alpha/Ribavarin Retreatment in Non-Responder Patients with Chronic Hepatitis C A DGReview of
    Message 1 of 1 , Oct 16, 2003
      Some Improvements Observed with Amantadine/Interferon-Alpha/Ribavarin
      Retreatment in Non-Responder Patients with Chronic Hepatitis C

      A DGReview of :"Randomized, controlled trial with IFN-alpha combined
      with ribavirin with and without amantadine sulphate in non-responders
      with chronic hepatitis C"
      Journal of Hepatology

      10/09/2003
      By Deanna M Green, PhD


      Greater sustained virologic response is observed with concomitant
      amantadine, interferon (IFN)-alpha, ribavarin treatment in patients
      with chronic hepatitis C who did not respond to initial antiviral
      treatment, and particularly in those with low baseline viremia,
      according to a recent German study.

      IFN-alpha therapy is commonly used to treat patients with chronic
      hepatitis C virus (HCV) infection and can be supplemented with
      ribavarin for an enhanced effect. Unfortunately though, 30 to 50% of
      treated patients do not respond to primary antiviral treatment.

      Conflicting data exists regarding whether these non-responders should
      be retreated with IFN-alpha and ribavarin and also whether another
      antiviral such as amantadine sulphate should be added to retreatment.

      Dr. Gerlinde Teuber at the Klinikum der Johann Wolfgang
      Goethe-Universitat, Frankfurt, Germany, and colleagues conducted a
      multi-centre, phase III, prospective study to evaluate the safety and
      efficacy of IFN-alpha/ribavarin retreatment with or without
      amantadine in patients with chronic hepatitis C who did not respond
      to previous individual or combinatorial therapy with these drugs.

      After stratification by HCV genotype, 225 patients were randomised to
      receive IFN-alpha 2b (5 MU daily for 4 weeks, 5 MU thrice weekly for
      20 weeks, followed by 3 MU thrice weekly for an additional 24 weeks)
      combined with ribavirin (1000-1200 mg/day) either with or without
      amantadine sulphate (200 mg/day) for 48 weeks. Efficacy and safety
      were assessed up to 24 weeks after treatment.

      Overall, 22% of all patients showed a sustained virologic response,
      and therefore undetectable HCV-RNA levels, at follow-up. While there
      was no statistically significant difference in the number of
      responders in each treatment group, triple retreatment had higher
      response rates, 25% compared to 18% in the non-amantadine group.

      Further analysis revealed that patients with HCV non-1 genotype,
      those with low pre-study viremia, and those who had undergone only 1
      previous antiviral treatment were more likely to respond to
      retreatment. Moreover, triple retreatment was more effective than
      non-amantadine treatment in patients with low baseline viremia.

      In addition, biochemical response as determined by normalisation of
      alanine aminotransferase (ALT) levels showed similar trends between
      groups as that observed for virologic response.

      A similar range and frequency of adverse events were observed in each
      treatment group. Most events were mild and reversible, though 8
      severe (WHO grade IV) events occurred.

      The authors conclude that "the addition of amantadine was well
      tolerated and led to an improvement of sustained virologic responses
      compared with retreatment with IFN-alpha/ribavarin alone, in
      particular in patients with low baseline viremia."

      Furthermore, they note that "the number of the previous antiviral
      treatments is an important response predictor for retreatment," and
      that "retreatment with IFN-alpha/ribavarin alone or in combination
      with amantadine cannot be recommended in non-responders with multiple
      previous antiviral treatment courses."

      J Hepatol 2003 Oct;39:4:606-13. "Randomized, controlled trial with
      IFN-alpha combined with ribavirin with and without amantadine
      sulphate in non-responders with chronic hepatitis C"


      __________________________________
      Do you Yahoo!?
      The New Yahoo! Shopping - with improved product search
      http://shopping.yahoo.com
    Your message has been successfully submitted and would be delivered to recipients shortly.